{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "d49104e2",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, re\n",
    "import numpy as np\n",
    "import pickle as pkl"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "d06eae30",
   "metadata": {},
   "outputs": [],
   "source": [
    "input_folder = \"../data/preprocessed_tika/\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "b07ee5ff",
   "metadata": {},
   "outputs": [],
   "source": [
    "file_to_text = {}\n",
    "for root, folder, files in os.walk(input_folder):\n",
    "    for file_name in files:\n",
    "        if not file_name.endswith(\"pkl\"):\n",
    "            continue\n",
    "        pdf_file = re.sub(\".pkl\", \"\", file_name)\n",
    "        \n",
    "        full_file = input_folder + \"/\" + file_name\n",
    "#         print (full_file)\n",
    "        with open(full_file, 'rb') as f:\n",
    "            text = pkl.load(f)\n",
    "        file_to_text[pdf_file] = text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "faf47569",
   "metadata": {},
   "outputs": [],
   "source": [
    "sap_regex = re.compile(r\"(?i)statistical\\s*analysis\\s*plan\")\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\bSAP\\b\")\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\bdata\\s*analysis\\s*plan\\b\")\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\bDAP\\b\")\n",
    "\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\b(effect\\s*(?:estimate|size)s?|reductions)\\b|\\d%+\\b\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "2a42af5b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\n\\t\\nStatistical\\tanalysis\\tplan,\\tdated\\t14\\tDecember\\t2016 \\n\\n'"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_to_text[\"TB-TB-2018-M-P-A.pdf\"][146]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "58c69b5e",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TB-TB-2018-DAR-PIA.pdf 68\n",
      "TB-TB-2018-M-P-A.pdf 161\n",
      "\t 18 \t lity (relative risk = 0.78,  95%CI = 0.59 -1.04). Significantl\n",
      "\t 88 \t ity (relative risk = 0.78,   95%CI = 0.59 -1.04). Significantl\n",
      "HIV-HIV-2016-Ayles-A Study of the HIV prevention Trials Network.pdf 166\n",
      "\t 12 \t ilto:epiwowa@jhmi.edu tel:%2B44%20%280%2920%207637%204314 mail\n",
      "\t 12 \t o:epiwowa@jhmi.edu tel:%2B44%20%280%2920%207637%204314 mailto:\n",
      "\t 12 \t iwowa@jhmi.edu tel:%2B44%20%280%2920%207637%204314 mailto:kalp\n",
      "\t 12 \t @jhmi.edu tel:%2B44%20%280%2920%207637%204314 mailto:kalpana.s\n",
      "\t 12 \t du tel:%2B44%20%280%2920%207637%204314 mailto:kalpana.sabapath\n",
      "\t 19 \t eral countries have reported  reductions in HIV prevalence, prevalence\n",
      "\t 21 \t ed to have contributed to the reductions in HIV prevalence  in Uganda,\n",
      "\t 23 \t  arm, as well  as significant reductions in morbidity in HIV-infected \n",
      "\t 23 \t al-level benefits in terms of reductions in morbidity and mortality  a\n",
      "\t 78 \t tly  unblinded to data on the effect size after 12 months. The DSMB wil\n",
      "\t 78 \t ysis.     Review of estimated effect size (by comparing HIV incidence b\n",
      "\t 112 \t anges in behaviour leading to reductions in  HIV prevalence in urban M\n",
      "TB-TB-2019-T-A-b.pdf 389\n",
      "\t 184 \t  whenever a HIV prevalence >  1%test is done, according to the\n",
      "HIV-HIV-2016-Laufer-Trimethoprim-Sulfamethoxazole-Chloroquine.pdf 100\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Papua New Guinea.pdf 90\n",
      "\t 35 \t , 80%  power for detecting an effect size of 30%). The primary endpoint\n",
      "HIV-HIV-2017-Abrams-IMPAACT P1101.pdf 85\n",
      "\t 5 \t : frieda@sun.ac.za       tel:27%2011%20989%209707 tel:(271)%20\n",
      "\t 5 \t eda@sun.ac.za       tel:27%2011%20989%209707 tel:(271)%20198-9\n",
      "\t 5 \t n.ac.za       tel:27%2011%20989%209707 tel:(271)%20198-99742 t\n",
      "\t 18 \t pected to lead to significant reductions in RAL concentrations in  chi\n",
      "NUT-A-2019-M-T.pdf 196\n",
      "   hospitalisation\t\n",
      "  infectial\ts\t\n",
      "   reduction\t\n",
      "  longer-­‐te\t\n",
      "  largenably\t\n",
      "\t 102 \t on that have led directly to  reductions in hospitalisation of childre\n",
      "\t 104 \t generally been attributed to  reductions in bacterial infections[45, 4\n",
      "\t 105 \t moxazole) resulted in a 57% (95%CI 24%–76%) reduction in all-c\n",
      "\t 106 \t rategies for maintaining risk reductions over the longer-term.    The \n",
      "\t 126 \t this to 3954 SA cases. As the effect sizes are reasonably large  on the \n",
      "HIV-HIV-2018-IMPAACT-P1112.pdf 155\n",
      "EDD-rotavirus-2017-Isanaka-ROSE.pdf 210\n",
      "NTD-Y-2019-M-Y.pdf 66\n",
      "NTD-Chagas-2015-Morillo-BENEFIT.pdf 76\n",
      "\t 11 \t  to 25% and stroke in 10% to 15%34. Sudden death is more frequ\n",
      "\t 38 \t  to 25% and stroke in 10% to 15%34. Sudden death is more frequ\n",
      "MAT-V-2018-R-M.pdf 193\n",
      "\t 8 \t sh, have witnessed remarkable reductions in under-5 mortality rates ov\n",
      "\t 11 \t average, 0.44 z-score units (95%CI 0.06, 0.82) higher than inf\n",
      "\t 54 \t ortions, incidence rates) and effect  estimates (i.e., regression coefficient\n",
      "\t 75 \t sh, have witnessed remarkable reductions in under-5 mortality rates ov\n",
      "\t 78 \t average, 0.44 z-score units (95%CI 0.06, 0.82) higher than inf\n",
      "\t 124 \t ortions, incidence rates) and effect  estimates (i.e., regression coefficient\n",
      "\t 153 \t te progress towards achieving reductions in child mortality in low-inc\n",
      "\t 167 \t te progress towards achieving reductions in child mortality in low-inc\n",
      "HIV-HIV-2018-GSK1265744.pdf 124\n",
      "\t 30 \t K Parameter (Geometric mean [95%CI] (CVb%)  AUC(0- )  (g•h/m\n",
      "\t 41 \t treatment delays and/or dose  reductions will also be recorded in the \n",
      "POL-P-2018-O-A-L.pdf 97\n",
      "MAT-Hypothermia-2018-Hansen-Electricity-free Infant Warmer.pdf 56\n",
      "\t 4 \t on die in their first day. 1  Reductions in the neonatal mortality mus\n",
      "EDD-T-2019-S-T.pdf 105\n",
      "\t 12 \t CI: 26.8 – 71.8%] and 52.0% [95%CI:   23.2-70.0%], respectivel\n",
      "\t 12 \t accine   increased to 87.1% [95%CI: 44.2-96.9%] compared to 52\n",
      "\t 12 \t .2-96.9%] compared to 52.3% [95%CI: -4.2%, 78.2%] for the unco\n",
      "\t 54 \t CI: 26.8 – 71.8%] and 52.0% [95%CI:   23.2-70.0%], respectivel\n",
      "\t 54 \t accine   increased to 87.1% [95%CI: 44.2-96.9%] compared to 52\n",
      "\t 54 \t .2-96.9%] compared to 52.3% [95%CI: -4.2%, 78.2%] for the unco\n",
      "NTD-Hookwork-2018-Keiser-Efficacy and safety of a single.pdf 51\n",
      "\t 7 \t led-trials.com%2fISRCTN86603231%2f \n",
      "TB-TB-2018-Piazza-A Phase 1b, Randomized, Double-blind.pdf 56\n",
      "MAL-Malaria-2019-Llanos-Cuentas-Tafenoquine vs. Primaquine to.pdf 402\n",
      "HIV-HIV-2017-Corey-HVTN703-HPTN081.pdf 193\n",
      "\t 20 \t cally significant   transient reductions in HIV viral load in adults w\n",
      "\t 47 \t f H1: PE > 0% under different effect sizes  PE = PE10 = PE30    Uncondit\n",
      "\t 53 \t elevant prevention   efficacy effect sizes if annual incidence rates are\n",
      "\t 70 \t correlate of protection (with effect size 15%, 60%,   85% efficacy) at \n",
      "\t 73 \t e Wilcoxon rank sum test. The effect size indexing a difference between\n",
      "\t 73 \t two groups. Four   correlates effect sizes are considered, ranging from \n",
      "\t 73 \t ed, ranging from the weakest (Effect Size 1) to   the strongest (Effect\n",
      "\t 73 \t t Size 1) to   the strongest (Effect Size 4). The results show that the\n",
      "\t 73 \t is moderate power to   detect Effect Size 3 phenotypic sieve effects (s\n",
      "\t 74 \t group  breakthrough HIV-1s.   Effect Size 3 is biologically plausible b\n",
      "\t 74 \t  each of the four   specified effect sizes PE(x) in Figure 4-11. For exa\n",
      "\t 74 \t Figure 4-11. For example, for Effect Size 3, the   most susceptible 11.\n",
      "\t 74 \t cacies is plausible. For this effect size there is 79.3% power to detec\n",
      "\t 75 \t  = 0%) for the four different effect sizes studied in Figure 4-11   PE(x\n",
      "\t 75 \t tudied in Figure 4-11   PE(x) Effect Size in Figure 1-16 Susceptible   \n",
      "\t 75 \t 0%]   Resistant   [PE = 0%]   Effect Size 4 41.9% 23.3%   Effect Size 3\n",
      "\t 75 \t   Effect Size 4 41.9% 23.3%   Effect Size 3 11.6% 2.8%   Effect Size 2 \n",
      "\t 75 \t    Effect Size 3 11.6% 2.8%   Effect Size 2 1.0% <0.1%   Effect Size 1 \n",
      "\t 75 \t    Effect Size 2 1.0% <0.1%   Effect Size 1 <0.1% <0.1%   Null Hypothes\n",
      "MAL-M-2019-A-S.pdf 92\n",
      "\t 60 \t .... 22    Crude and adjusted effect estimates..............................\n",
      "\t 63 \t . No interim  analysis of the effect size was conducted.   A total of 2\n",
      "\t 74 \t ing and standalone estimates  Effect estimates will be computed and presente\n",
      "\t 74 \t for each site separately. All effect  estimates will take the cluster design \n",
      "\t 77 \t will be calculated as  (RRR=100%x[1-RR]) and can be expressed \n",
      "\t 78 \t nalysis    Crude and adjusted effect estimates  The primary analyses will be\n",
      "\t 79 \t  >10% relative difference in  effect estimate [e.g. RR 1.4 vs RR 1.6]) the \n",
      "\t 89 \t ach group, and the  estimated effect size and its  precision (such as 9\n",
      "\t 89 \t f both  absolute and relative effect  sizes is recommended       Ancillar\n",
      "\t 91 \t s \t10.3.1. Crude and adjusted effect estimates \t10.3.2. Adjustment for basel\n",
      "NTD-E-2017-A-A.pdf 60\n",
      "HIV-HIV-2017-Bekker-HVTN100.pdf 154\n",
      "MAL-Malaria-2019-Tinto-Extension to study MALARIA-055 PRI.pdf 100\n",
      "NUT-NUT-2019-A-I.pdf 132\n",
      "\t 53 \t action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0093776&represe\n",
      "\t 53 \t action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0093776&represe\n",
      "\t 53 \t action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0093776&represe\n",
      "\t 56 \t .nlm.nih.gov/pubmed/?term=Br%26%23x000fc%3Bssow%20H%5Bauth%5D \n",
      "\t 68 \t ine report 2011.     - “…with effect size=0.3…” – Should not the effect\n",
      "\t 68 \t t size=0.3…” – Should not the effect size be 0.4 based on information a\n",
      "\t 68 \t  information above. Why this  effect size is chosen? Justify. May be we\n",
      "\t 68 \t stify why we cannot choose an effect size smaller  than this? This migh\n",
      "\t 68 \t gnificance.   - Response- The effect size has been calculated based on \n",
      "\t 68 \t p.  According to literatures, effect size is small if ≤0.2 and medium i\n",
      "\t 68 \t  if ≤0.5. We have selected an effect size  between small and medium bas\n",
      "HIV-HIV-2018-M-A.pdf 182\n",
      "HIV-HIV-2017-L-I.pdf 148\n",
      "TB-TB-2019-M-A.pdf 115\n",
      "VAC-G-2016-VAC-G-2016-V.pdf 48\n",
      "\t 45 \t V-1&_user=7789910&_coverDate=12%2F11%2F2009&_alid=1269910819&_\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\t 45 \t user=7789910&_coverDate=12%2F11%2F2009&_alid=1269910819&_rdoc=\n",
      "\t 45 \t V-1&_user=7789910&_coverDate=12%2F11%2F2009&_alid=1269910819&_\n",
      "\t 45 \t user=7789910&_coverDate=12%2F11%2F2009&_alid=1269910819&_rdoc=\n",
      "\t 45 \t V-1&_user=7789910&_coverDate=12%2F11%2F2009&_alid=1269910819&_\n",
      "\t 45 \t user=7789910&_coverDate=12%2F11%2F2009&_alid=1269910819&_rdoc=\n",
      "HIV-HIV-2016-N-S.pdf 358\n",
      "\t 338 \t  explore the influence on the effect size of those participants   repor\n",
      "VAC-Shigellosis-2019-Raqib-Shigella WRSS1 Vaccine trial in Bangladesh.pdf 64\n",
      "HIV-HIV-2017-Evolocumab-AMG145.pdf 95\n",
      "TB-TB-2015-D-A.pdf 124\n",
      "POL-P-2016-G-T.pdf 62\n",
      "\t 10 \t f 10%. Under the same assumed effect size  this sample size will provid\n",
      "\t 47 \t f 10%. Under the same assumed effect size this sample size will provide\n",
      "TB-TB-2019-Suliman-A Phase I_IIa Double-Blind.pdf 75\n",
      "MAT-Anemia-2015-Etheredge-Prenatal Iron Supplements Safety and.pdf 46\n",
      "\t 9 \t %; P = 0.017) [123]. Observed reductions in the prevalence of low birt\n",
      "\t 27 \t atment effects expressed as % reductions) based on a 2-sided  test for\n",
      "\t 28 \t ve good power to detect a 35% effect size, for placental malaria rates \n",
      "\t 28 \t ve good power to detect a 30% effect size and excellent power to detect\n",
      "\t 28 \t cellent power to detect a 40% effect size.     Continuous Variables: Th\n",
      "\t 28 \t ressed as percent changes in  effect size) based on a 2-sided test for \n",
      "\t 28 \t have  good power to detect an effect size of 8.5%, and excellent power \n",
      "\t 28 \t good power to  detect an 8.5% effect size, and excellent power to detec\n",
      "\t 28 \t  excellent power to detect an effect size of 10% or greater.     Matern\n",
      "\t 28 \t ave good power to detect a 5% effect size, and excellent power to detec\n",
      "\t 28 \t (Units)    Mean  SD  Minimal  effect size  for 80%  power    Power for \n",
      "\t 29 \t ave good power to detect a 2% effect size, and  excellent power to dete\n",
      "HIV-HIV-2016-R-E.pdf 452\n",
      "HIV-HIV-2019-H-S.pdf 242\n",
      "\t 10 \t variates in order to  achieve effect estimates with greater precision.      \n",
      "\t 13 \t ional cohort  studies showing reductions in HIV transmission by ART in\n",
      "\t 14 \t Finally, ART (despite 10-fold reductions in drug price over the last d\n",
      "\t 44 \t dy power and the precision of effect  estimates if communities are matched we\n",
      "\t 48 \t d to improve the precision of effect  estimates, to identify the causal effec\n",
      "\t 54 \t  improve the precision of our effect estimates, by  making use of individual\n",
      "\t 57 \t hould  provide a conservative effect estimate given the potential for covar\n",
      "\t 57 \t mately 2%. Figure 1 shows the effect size we are powered to detect unde\n",
      "\t 58 \t sample sizes), homogeneity in effect size, and a  constant coefficient \n",
      "\t 58 \t stigate heterogeneity  in the effect size. By this method of simulation\n",
      "\t 71 \t  This benefit may accrue from reductions in  immune activation and sys\n",
      "\t 97 \t ional cohort  studies showing reductions in HIV transmission by ART in\n",
      "\t 98 \t Finally, ART (despite 10-fold reductions in drug price over the last d\n",
      "\t 131 \t dy power and the precision of effect  estimates if communities are matched we\n",
      "\t 139 \t hould  provide a conservative effect estimate given the potential for covar\n",
      "\t 139 \t mately 2%. Figure 1 shows the effect size we are powered to detect unde\n",
      "\t 152 \t  This benefit may accrue from reductions in  immune activation and sys\n",
      "\t 176 \t  and type I error control for effect estimates based on this approach.  2.5 \n",
      "\t 181 \t on (km) and to detect smaller effect sizes under more plausible km value\n",
      "\t 182 \t 000  2 0  2 5  3 0  3 5  4 0  Effect Size Detected with 80% Power for a\n",
      "\t 182 \t 40 km=0.30 km=0.20  Figure 1: Effect size (in percent reduction) that w\n",
      "\t 183 \t there was a constant relative effect size of 35% within each region. Co\n",
      "\t 183 \t r. The x-axis is the absolute effect size in percent and the y-axis pow\n",
      "\t 183 \t  E), even though the absolute effect size was increased.  2. Adjusting \n",
      "\t 183 \t imator and Scenario  Absolute Effect Size (in percent)  P o w  e r a  b\n",
      "\t 197 \t . URL http://dx.doi.org/10.1371%2Fjournal.pone. 0016986.  29  \n",
      "\t 201 \t for baseline factors. Primary effect estimates will be reported on a relativ\n",
      "\t 206 \t  and type I error control for effect estimates based on this approach.  In t\n",
      "\t 210 \t on (km) and to detect smaller effect sizes under more plausible km value\n",
      "\t 211 \t 200 3400  2 5  3 0  3 5  4 0  Effect Size Detected with 80% Power for a\n",
      "\t 211 \t =0.4 km=0.3 km=0.2  Figure 1: Effect size (in percent reduction) that w\n",
      "\t 211 \t 400  2 0  2 5  3 0  3 5  4 0  Effect Size Detected with 80% Power   Wit\n",
      "\t 211 \t m from 0.3 to 0.25  Figure 2: Effect size (in percent reduction) that w\n",
      "\t 237 \t . URL http://dx.doi.org/10.1371%2Fjournal.pone. 0016986.  [35]\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Haiti.pdf 67\n",
      "\t 29 \t , 80%  power for detecting an effect size of 30%). The primary endpoint\n",
      "MAT-MAT-2018-G-F.pdf 60\n",
      "\t 9 \t rnal and child mortality, and reductions in the size   and cost of ele\n",
      "\t 25 \t s per 1000 deliveries, target reductions of 20% to 25%, at ICC of 0.00\n",
      "EDD-R-2017-G-V.pdf 125\n",
      "\t 53 \t icacy, there were substantial reductions in shedding (at any time) in \n",
      "MAT-HIV-2016-Fowler-PROMISE.pdf 902\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 57 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 57 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 57 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 58 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 135 \t  the potential  absolute risk reductions associated with treatment in \n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 150 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 181 \t ry precisely, and substantial reductions in plasma HIV  RNA concentrat\n",
      "\t 196 \t dels for estimating treatment effect sizes.  In light of the conservativ\n",
      "\t 325 \t d the potential absolute risk reductions associated with treatment  in\n",
      "\t 351 \t ry precisely, and substantial reductions in plasma HIV RNA concentrati\n",
      "\t 363 \t dels for estimating treatment effect sizes. In light of  the conservativ\n",
      "\t 372 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 372 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 372 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 372 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 372 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 372 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 372 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 372 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 373 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 373 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 373 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 474 \t d=Search&Term=%22Squires%20K%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 474 \t =Search&Term=%22Pozniak%20AL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 474 \t rch&Term=%22Pierone%20G%20Jr%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 474 \t &Cmd=Search&Term=%22Study%20907%20Team%22%5BCorporate%20Author\n",
      "\t 474 \t h&Term=%22Study%20907%20Team%22%5BCorporate%20Author%5D&itool=\n",
      "\t 474 \t ch&Term=%22Van%20Rompay%20KK%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 474 \t &Term=%22Durand-Gasselin%20L%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 474 \t Search&Term=%22Brignolo%20LL%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 559 \t d the potential absolute risk reductions associated with treatment in \n",
      "\t 575 \t Cmd=Search&Term=%22Emery%20S%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 575 \t =Search&Term=%22Neuhaus%20JA%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 575 \t Search&Term=%22Phillips%20AN%22%5BAuthor%5D&itool=EntrezSystem\n",
      "\t 588 \t ry precisely, and substantial reductions in plasma HIV RNA concentrati\n",
      "\t 590 \t e in power, provided that the effect size in these two extra days is co\n",
      "\t 593 \t formed to examine whether the effect size for the primary efficacy  ana\n",
      "\t 607 \t dels for estimating treatment effect sizes.  In light of  the conservati\n",
      "\t 748 \t d the potential absolute risk reductions associated with treatment in \n",
      "\t 777 \t ry precisely, and substantial reductions in plasma HIV RNA concentrati\n",
      "\t 779 \t e in power, provided that the effect size in these two extra days in co\n",
      "\t 782 \t formed to examine whether the effect size for the primary efficacy  ana\n",
      "\t 791 \t dels for estimating treatment effect sizes. In light of  the conservativ\n",
      "TB-TB-2018-H-A.pdf 365\n",
      "HIV-HIV-2016-HVTN114.pdf 126\n",
      "\t 17 \t imens elicited similar 61-64% reductions in the per challenge risk of \n",
      "\t 32 \t oups for detecting a range of effect sizes. Effect size is the differenc\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\t 32 \t ting a range of effect sizes. Effect size is the difference of means pe\n",
      "\t 32 \t mple,  the power of detecting effect size of 1 between 2 groups of size\n",
      "\t 32 \t p means corresponding to this effect size will depend on the variation \n",
      "\t 32 \t Difference in 2 group Means   Effect Size n1 = n2 = 18 n1 = n2 = 36 n1 \n",
      "\t 34 \t onses, the power of detecting effect size of 1 between 2  groups of siz\n",
      "HIV-HIV-2018-Long-acting Cabotegravir Plus Long-acting Rilpivirine.pdf 242\n",
      "\t 29 \t  Dose Modifications:  No dose reductions, modifications, or changes in\n",
      "\t 59 \t  Dose Modifications:  No dose reductions, modifications, or changes in\n",
      "\t 64 \t 3) 53 (87) 157 (87) 46 (74)  95%CI  Proportion  (82, 98) (74, \n",
      "\t 64 \t 5) 53 (87) 156 (86) 46 (74)  95%CI  Proportion  (78, 95) (76, \n",
      "\t 64 \t 0) 53 (87) 149 (82) 44 (71)  95%CI  Proportion  (70, 90) (70, \n",
      "\t 64 \t 5) 51 (84) 137 (76) 39 (63)  95%CI  Proportion  (57,80) (64,86\n",
      "\t 65 \t K Parameter (Geometric mean [95%CI] (CVb%)  AUC(0-) (g.h/mL)\n",
      "\t 68 \t K Parameter (Geometric mean [95%CI] (CVb%)  AUC(0- )  (g•h/m\n",
      "\t 75 \t K Parameter (Geometric mean [95%CI] (CVb%)  AUC(0- )  (g•h/m\n",
      "\t 143 \t ce.  No toxicity-related dose reductions of IP will be allowed.  IP sh\n",
      "NUT-S-2018-R-S.pdf 113\n",
      "\t 8 \t ical period leads to greater  reductions in child undernutrition than \n",
      "\t 43 \t family ration.  The estimated effect size is therefore  set to 0.325 HA\n",
      "\t 43 \t  (and the small difference in effect size found between Haiti [with  fo\n",
      "\t 98 \t amily ration.  The estimated  effect size is therefore set to 0.325 HAZ\n",
      "\t 98 \t (and the small difference in  effect size found in Haiti and Peru), the\n",
      "VAC-Tdap-2019-Sancovski-A Post-marketing, Observational, Retrospective.pdf 82\n",
      "\t 50 \t . -Early miscarriage:  Up to 20%of  pregnancies. -Late miscarr\n",
      "NTD-t-2017-M-E.pdf 118\n",
      "\t 92 \t ov/pubmed?term=%22Camara%20M%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t ov/pubmed?term=%22Camara%20O%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t v/pubmed?term=%22Ilboudo%20H%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t v/pubmed?term=%22Sakande%20H%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t nih.gov/pubmed?term=%22Kabor%C3%A9%20J%22%5BAuthor%5D http://w\n",
      "\t 92 \t .gov/pubmed?term=%22Kabor%C3%A9%20J%22%5BAuthor%5D http://www.\n",
      "\t 92 \t bmed?term=%22Kabor%C3%A9%20J%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t gov/pubmed?term=%22N'Dri%20L%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t pubmed?term=%22Jamonneau%20V%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 92 \t /pubmed?term=%22Bucheton%20B%22%5BAuthor%5D http://www.ncbi.nl\n",
      "MAL-M-2018-D-C.pdf 74\n",
      "NTD-D-2017-S-P.pdf 85\n",
      "HIV-HIV-2016-Garrett-HVTN108.pdf 155\n",
      "\t 51 \t very low chance of achieving 40%VE;  note that a perfect binar\n",
      "\t 51 \t ery low chance of  achieving 40%VE.   4. The fourth category i\n",
      "\t 51 \t ery  low chance of achieving 40%VE.    \n",
      "HIV-HIV-2018-Labhardt-CASCADE.pdf 90\n",
      "TB-TB-2019-Dawson-A Phase 2 Open‐Label Partially .pdf 112\n",
      "MAL-MAL-2018-Dorsey-PROMOTE Birth Cohort 1.pdf 94\n",
      "\t 14 \t nd 51I mutations (OR = 10.7, 95%CI 1.8-64.4, p = 0.009).    We\n",
      "PNE-P-2019-C-P.pdf 91\n",
      "\t 88 \t ns Program Network. Sustained reductions in invasive pneumococcal  dis\n",
      "\t 88 \t .org/content/documents/21252030%20Agenda%20for%20Sustaina ble%\n",
      "HIV-HIV-2019-Venter-ADVANCE.pdf 184\n",
      "\t 44 \t ivsoc.org/upload/documents/2013%20ART%20Guidelines- Short%20Co\n",
      "\t 44 \t FINAL%20draft%20guidelines%2014%20March%202013.pdf.  Accessed \n",
      "\t 44 \t ivsoc.org/upload/documents/2013%20ART%20Guidelines-Short%20Com\n",
      "\t 44 \t FINAL%20draft%20guidelines%2014%20March%202013.pdf http://www.\n",
      "\t 44 \t ivsoc.org/upload/documents/2013%20ART%20Guidelines-Short%20Com\n",
      "\t 44 \t FINAL%20draft%20guidelines%2014%20March%202013.pdf \n",
      "\t 100 \t ivsoc.org/upload/documents/2013%20ART%20Guidelines- Short%20Co\n",
      "\t 100 \t FINAL%20draft%20guidelines%2014%20March%202013.pdf. Accessed 4\n",
      "\t 100 \t ivsoc.org/upload/documents/2013%20ART%20Guidelines-Short%20Com\n",
      "\t 100 \t FINAL%20draft%20guidelines%2014%20March%202013.pdf http://www.\n",
      "\t 100 \t ivsoc.org/upload/documents/2013%20ART%20Guidelines-Short%20Com\n",
      "\t 100 \t FINAL%20draft%20guidelines%2014%20March%202013.pdf http://hivt\n",
      "HIV-HIV-2019-K-C.pdf 191\n",
      "\t 11 \t ce was reported to be 18.4% (95%CI  16.1-21.1) in the Northern\n",
      "\t 12 \t  Rustenburg [14], 6.5/100wy (95%CI 4.4–9.2) in Vulindlela,   6\n",
      "\t 12 \t  in Vulindlela,   6.4/100wy (95%CI 2.6–13.2) in Durban 14.8/10\n",
      "\t 12 \t lela)  women  was 9.0/100wy (95%CI 5.3-14.3) and  9.1/100wy  (\n",
      "\t 12 \t I 5.3-14.3) and  9.1/100wy  (95%CI 6.6-12.3) respectively  in \n",
      "\t 25 \t alence increased from 32.4% (95%CI 27.6-37.6) in 2001 to  40.0\n",
      "\t 25 \t ated  mortality rate of 5.2 (95%CI 2.9-7.5) /100pyo in young w\n",
      "PNE-Pneumonia-2019-Alexander-LEAP2.pdf 175\n",
      "\t 20 \t the inverse  variance of each effect size) pooled population from this \n",
      "\t 81 \t  the inverse variance of each effect size) pooled  population from this\n",
      "MAT-Cervical Disease-2019-Greene-LEEP.pdf 296\n",
      "\t 96 \t page are based on a power of 80%to 2012   detect a treatment g\n",
      "TB-TB-2018-Churchyard-Bedaquiline-Delamanid.pdf 119\n",
      "\t 19 \t 2% and 25%, respectively, but reductions in BDQ and  M2 metabolite con\n",
      "MAL-Malaria-2019-Foy-RIMDAMAL.pdf 58\n",
      "\t 14 \t ial capacity, and significant reductions  (>77%) in sporozoite rates f\n",
      "\t 14 \t  While very transient, these  reductions are in-line with changes seen\n",
      "\t 17 \t ed, and result in significant reductions in Plasmodium spp. transmissi\n",
      "TB-TB-2019-N-S.pdf 224\n",
      "\t 82 \t l outcome and a mortality of 11%11.    Van Deun et al (2010)1 \n",
      "\t 87 \t pared to 125  days, HR 2.44, 95%CI 1.57-3.80).  However, there\n",
      "NUT-Stunting-2019-Humphrey-SHINE.pdf 91\n",
      "\t 25 \t oup we will be able to detect effect sizes ranging from 35% to 40% of on\n",
      "\t 25 \t ve, we will be able to detect effect sizes  on the order of 25% of one s\n",
      "\t 25 \t   sampled per cluster.  These effect sizes are small compared to the obs\n",
      "\t 90 \t /pubmed?term=%22Zijenah%20LS%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t /pubmed?term=%22Humphrey%20J%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t du/pubmed?term=%22Nathoo%20K%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t du/pubmed?term=%22Malaba%20L%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t ubmed?term=%22Zvandasara%20P%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t u/pubmed?term=%22Mahomva%20A%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t edu/pubmed?term=%22Iliff%20P%22%5BAuthor%5D http://www.ncbi.nl\n",
      "\t 90 \t u/pubmed?term=%22Mbizvo%20MT%22%5BAuthor%5D \n",
      "PNE-Pneumonia-2018-Keenan-Mortality Reduction After Oral Azithromycin.pdf 184\n",
      "\t 160 \t ovide  80% power to detect an effect size of 35%.  9  \n",
      "\t 163 \t  • The effect size is 0.15.  The number of clust\n",
      "\t 163 \t Z. Zhou, pers. comm.).  • The effect size is 0.15.  The number of clust\n",
      "\t 164 \t to follow-up per year.  • The effect size is 0.15.  The number of clust\n",
      "\t 176 \t  follow-up per year.    • The effect size is 0.15.   • The desired powe\n",
      "\t 177 \t pproximately 41% power for an effect size  of 15% for Malawi alone.   3\n",
      "\t 177 \t  Zhou, pers. comm.).    • The effect size is 0.15.    • The desired pow\n",
      "\t 177 \t proximately 84% power for an  effect size of 15% for Niger alone.   \n",
      "\t 178 \t  follow-up per year.    • The effect size is 0.15.    • The desired pow\n",
      "\t 178 \t proximately  31% power for an effect size of 15% for Tanzania alone.   \n",
      "\t 178 \t  than 80% power to  detect an effect size of approximately 0.10, or ten\n",
      "EDD-Cholera-2016-Qadri-Shanchol.pdf 124\n",
      "TB-TB-2020-John-Stewart-iTIPS.pdf 85\n",
      "\t 18 \t sequent   active TB (aOR 4.8 95%CI 1.2-19.7, p=0.03) and with \n",
      "VAC-Ecoli-2019-Qadri-ETVAX.pdf 65\n",
      "HIV-HIV-2018-Havlir-SEARCH.pdf 101\n",
      "\t 14 \t ional cohort  studies showing reductions in HIV transmission by ART in\n",
      "\t 15 \t Finally, ART (despite 10-fold reductions in drug price over the last d\n",
      "\t 60 \t y power  and the precision of effect estimates if communities are matched we\n",
      "\t 68 \t should provide a conservative effect estimate given the potential for covar\n",
      "\t 68 \t tely 1.3%. Figure 1 shows the effect size we are powered to detect in P\n",
      "\t 81 \t  This benefit may accrue from reductions in  immune activation and sys\n",
      "HIV-HIV-2016-Kurth-High-yield HIV testing, facilitated linkage to care.pdf 111\n",
      "\t 62 \t needed to detect a particular effect size with at least 80%  power. Rat\n",
      "HIV-HIV-2017-Corey-HVTN704-HPTN085.pdf 175\n",
      "\t 19 \t tically significant transient reductions in HIV viral load in adults w\n",
      "\t 44 \t f H1: PE > 0% under different effect sizes  PE = PE10 = PE30    Uncondit\n",
      "\t 47 \t mary null hypothesis H0: PE ≤ 0%with 900 control  recipients a\n",
      "\t 50 \t relevant prevention  efficacy effect sizes if annual incidence rates are\n",
      "\t 65 \t correlate of protection (with effect size 15%, 60%, 85% efficacy)  at t\n",
      "\t 66 \t r for the PE = 15%,  60%, 85% effect size if 25%, 50%, 25% of PYRs at r\n",
      "\t 69 \t e Wilcoxon rank sum test. The effect size indexing a difference between\n",
      "\t 69 \t e two groups. Four correlates effect sizes are  considered, ranging from\n",
      "\t 69 \t ed, ranging from the weakest (Effect Size 1) to the strongest (Effect S\n",
      "\t 69 \t ect Size 1) to the strongest (Effect Size 4). The  results show that th\n",
      "\t 69 \t e is moderate power to detect Effect Size 3 phenotypic sieve effects  (\n",
      "\t 70 \t group  breakthrough HIV-1s.   Effect Size 3 is biologically plausible b\n",
      "\t 70 \t or each of the four specified effect sizes PE(x) in Figure  4-12. For ex\n",
      "\t 70 \t igure  4-12. For example, for Effect Size 3, the most susceptible 11.6%\n",
      "\t 70 \t cacies is plausible. For this effect size there is 79.3% power  to dete\n",
      "\t 70 \t  = 0%) for the four different effect sizes studied in Figure 4-12   PE(x\n",
      "\t 70 \t tudied in Figure 4-12   PE(x) Effect Size in Figure 1-16 Susceptible  [\n",
      "\t 70 \t 00%]   Resistant  [PE = 0%]   Effect Size 4 41.9% 23.3%   Effect Size 3\n",
      "\t 70 \t   Effect Size 4 41.9% 23.3%   Effect Size 3 11.6% 2.8%   Effect Size 2 \n",
      "\t 70 \t    Effect Size 3 11.6% 2.8%   Effect Size 2 1.0% <0.1%   Effect Size 1 \n",
      "\t 70 \t    Effect Size 2 1.0% <0.1%   Effect Size 1 <0.1% <0.1%   Null Hypothes\n",
      "\t 79 \t hloride for Injection USP,  0.9%to the 100 mL IV bag of Sodium\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "HIV-HIV-2016_Tebas-A5354.pdf 133\n",
      "HIV-HIV-2016-Weinberg-NICHP1091.pdf 93\n",
      "MAL-Malaria-2016-Valencia-Phase 1 and 2a Clinical.pdf 61\n",
      "\t 47 \t y group and percentages and  95%CI intervals will be estimated\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Indonesia.pdf 108\n",
      "\t 31 \t A, 80% power for detecting an effect size of 30%). The primary endpoint\n",
      "VAC-M-2015-L-W.pdf 193\n",
      "\t 50 \t nalysis: calculate two-sided 95%CI for the difference in propo\n",
      "\t 51 \t  91.   • Calculate two-sided 95%CI for difference in proportio\n",
      "\t 52 \t bserved by day 364 the upper 95%CI  will be 3.6% (1 in 28).   \n",
      "\t 53 \t  is to calculate the 2-sided 95%CI for the difference in propo\n",
      "\t 114 \t nalysis: calculate two-sided 95%CI for the difference in propo\n",
      "\t 115 \t  91.   • Calculate two-sided 95%CI for difference in proportio\n",
      "\t 116 \t bserved by day 364 the upper 95%CI  will be 3.6% (1 in 28).   \n",
      "\t 117 \t  is to calculate the 2-sided 95%CI for the difference in propo\n",
      "\t 141 \t etation on examination of the effect size, confidence interval and p va\n",
      "\t 163 \t tes  Seropositivity  *    OR 95%CI P   value Age (months):    \n"
     ]
    }
   ],
   "source": [
    "for file, pages in file_to_text.items():\n",
    "    print (file, len(pages))\n",
    "    for page_no, page_text in enumerate(pages):\n",
    "        matches = sap_regex.finditer(page_text)\n",
    "               \n",
    "        for match in matches:\n",
    "            l = int(np.max((0, match.start() - 30)))\n",
    "            r = int(np.min((len(page_text), match.end() + 30)))\n",
    "            print (\"\\t\", page_no, \"\\t\",  page_text[l:r].replace(\"\\n\", \" \"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "9322eba9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "76"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(files)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dafcb96e",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
